Objectives-Immunological abnormalities in idiopathic dilated cardiomyopathy (DCM) include an increase in soluble interleukin(IL)-2 receptor, disease specific cardiac autoantibodies, an HLA-DR4 association, and familial aggregation of disease; however, cytokine profiles have not been defined. Serum concentrations of IL-2, IL-4, IL-10, and IL-12 were measured in patients with DCM (WHO criteria), relatives with asymptomatic left ventricular enlargement (LVE), patients with ischaemic heart failure (IHD), and healthy controls. Design-Serum from 20 individuals from each of the four groups was assayed for cytokine concentrations by a commercial enzyme linked immunosorbent assay. Results-IL-2 concentrations were abnormally increased in DCM patients and relatives with LVE. Concentrations of IL-10 were increased in DCM patients. Concentrations of IL-4 and IL-12 were not increased in any of the groups. Conclusion-These abnormalities may reflect defective/inappropriate T cell function in patients with DCM and in their relatives with LVE.
Idiopathic dilated cardiomyopathy is a chronic heart muscle disease of unknown aetiology characterised by a dilated and poorly contractile left ventricle.' It usually affects young individuals, and is the commonest indication in the United Kingdom for cardiac transplantation; this is the only curative treatment but its use has been limited by the supply of donor organs. 2 Animal models have emphasised the role of the T cell in the induction of autoimmune myocarditis3 and of cytokines in the maintenance of viral myocarditis,4 but direct evidence of cellular autoimmunity in human DCM is lacking. Indirect evidence for an immune pathogenesis for this condition includes the presence of abnormal concentrations of soluble interleukin 2 receptor,5 organ and disease specific autoantibodies by immunofluorescence,6 abnormal cardiac endothelial major compatibility complex class II antigen expression7 a specific human leucocyte antigen association with the DR-4 haplotype,78 and familial aggregation of disease.9 10 Prospective family screening has identified a subset of asymptomatic first degree relatives with left ventricular enlargement consistent with early DCM'°; immune abnormalities in these individuals include the presence of cardiac autoantibodies. II Previous studies of cytokine concentrations in DCM have used methods of limited sensitivity and have not defined the Thl/Th2-type of the immune response.'2 T-helper (Th) clones can be classified according to the cytokines that they produce; definitive Thl cells produce IL-2, IL-12, and interferon y (IFN-y) and are important in cellular immunity whereas definitive Th2 cells produce IL-4, IL-10, and IL-13 and predominate in humoral immunity. ' For assessment of IL-10, biotinylated anti-IL-10 antibody conjugate and then streptavidinhorseradish peroxidase were used before the addition of chromogen. In each case duplicate readings were converted into pg/ml using the standard curves generated with each plate. Concentrations were defined as abnormal if they were above the lowest standard concentration used in the assay (IL-2 and IL-4, 31-2 pg/ml; IL-12, 7-8 pg/ml; IL-10, 15-6 pg/ml). Intra-assay variability of three (IL-10 and IL-12) or four (IL-2 and IL-4) known concentrations assayed in replicates of 20 (10 for IL-10) were 6-1%-9-5% for IL-2; 3 9%-7-3% for IL-4; 4-6%-7-7% for IL-10, and 1 1%-1 5% for IL-12.
CLINICAL CHARACTERISTICS OF PATIENTS WITH ISCHAEMIC HEART DISEASE
The disease control population consisted of 20 patients with heart failure secondary to ischaemic heart disease (age 66 (8), range (17) pg/ml, P = 0-002) or healthy controls 17 (22) pg/ml, P < 0-001). Similarly IL-10 concentrations were greater in patients with DCM than in those with IHD (41 (17) pg/ml v 4 (3) pg/ml; P < 0-001) or healthy controls 2 (1) pg/ml; P < 0-001) (figs 1 and 2).
Abnormal cytokine profiles in patients with idiopathic dilated cardiomyopathy and their asymptomatic relatives Abnormal concentrations of IL-2 were more common in DCM patients than patients with IHD (13 out of 20 (65%) v 1 out of 20 (5%); P = 0-0001) or healthy controls (3 out of 20 (15%); P = 0-001). Raised IL-10 concentrations were also detected more frequently in DCM patients than IHD patients (10 out of 20 (50%) v 1 out of 20 (5%); P = 0-001) or healthy controls (none; P = 0-0003 
Discussion
In this study abnormal concentrations of IL-2 were found in 65% of patients with dilated cardiomyopathy and in 60% of their asymptomatic relatives with left ventricular enlargement compared with 5% of patients with ischaemic heart disease and 15% of healthy controls. Raised IL-10 concentrations were present in 50% of patients with dilated cardiomyopathy but in only 5% of those with ischaemic heart disease and in none of the relatives or healthy controls. These observations suggest that an increase in these cytokines is specific to dilated cardiomyopathy and not an epiphenomenon related to heart failure per se. This supports the concept that left ventricular enlargement may represent early DCM.
Our findings are consistent with previous reports of increased concentrations of soluble interleukin-2 receptor in about a third of patients with DCM5 as well as in patients with myocarditis.'8 T-cell activation is accompanied by the release into the circulation of interleukin-2 which acts via a specific receptor on the cell surface, but concentrations of cytokine receptor in the serum are only an indirect assessment of T cell function. A recent study found that abnormal concentrations of IL-2 were present in only 4% of a cohort of Asian patients with DCM, but not in the ischaemic heart disease patients or healthy controls12; the assay used in that study was of low sensitivity and patients with a comparable degree of heart failure secondary to ischaemic heart disease were not evaluated. Experimental models of autoimmune myocarditis have emphasised the role of T cells in induction of disease3; the observation-in the present study of an increase in both IL-2 and IL-i 0 but not IL-4 or IL-12 in a high proportion of patients with DCM in comparison with controls is compatible with a ThO-type profile, in which there is an increase in cytokine concentrations associated with both Thl-type (gamma-IFN, IL-2, and IL-12) and Th2-type (IL-4, IL-5, IL-6, and IL-10) immune function.
Left ventricular dysfunction was common among the asymptomatic relatives of patients with DCM in whom it may represent early disease.9 10 An immune component to disease pathogenesis has been recently suggested by the detection of an organ and disease specific anti-heart antibody by immunofluorescence in 30% of these relatives, particularly gravis.22 It is possible that a Thl-type immune response as suggested by the occurrence of high serum IL-2 concentrations shown in DCM patients in this study may be either protective or pathogenic. The subsequent development of raised IL-10, which is consistent with a Th2 type response, could be pathogenic owing to down-regulation of antigen presentation by monocyte/macrophages and/or to reduced production of IFN-g, which is a powerful immunomodulator, and anti-viral Thl type cytokine. Coxsackie B3 virus is an important cause of myocarditis and has been associated with monocyte/macrophage induced inflammatory responses which may in themselves be responsible for the raised IL-10 concentrations in this study.23 Nevertheless, abnormal cytokine mediated immune responses to this virus may be clinically relevant in the pathogenesis of DCM. Failure of an appropriate immune switch to T helper (Th2-type) cells producing IL-4 at the onset of clinically significant disease in DCM could also lead to IL-1 0 production; this explanation would be consistent with the finding in the present study of an absence of detectable IL-4 in any of the patients.
Raised concentrations of IL-10 may have been produced by monocyte/macrophage cells24-if these cells were activated by a different pathogenic mechanism in DCM patients. In the absence of direct measurements of Th-1 or Th-2 cytokine profiles in isolated lymphocyte populations (such as by fluorexene activated cell sorter (FACS) analysis of intracellular cytokines), this remains a strong possibility. We are addressing these issues by longitudinally studying serum and isolated lymphocyte analysis of DCM patients and their asymptomatic relatives with left ventricular enlargement. Quantitative analysis of mRNA of different cytokines from different cell types as well as cardiac tissue, in addition to in situ hybridisation analysis of cardiac biopsies may clarify these issues. Further studies may suggest a therapeutic strategy for stimulating or inhibiting immunoregulatory cytokines and their antagonists in DCM.
In conclusion, DCM is associated with an activated immune response involving both IL-2 and IL-1 0, whereas IL-2 was raised only in the serum of asymptomatic relatives with LVE.
The data do not prove a causal or protective role for IL-2 or IL-10 in DCM, but they do strengthen support for an immune pathogenesis in this disease. Longitudinal study of DCM patients and their relatives may permit exploration of specific immunomodulatory treatments.
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